

CURRICULUM VITAE

Aisling R. Caffrey, Ph.D., M.S.

Contact Information

Citizenship: United States

URI Office Address: University of Rhode Island College of Pharmacy
7 Greenhouse Road, Room 265B, Kingston, RI 02881
Aisling_Caffrey@uri.edu | 401-874-5320

VA Office Address: Veterans Affairs Medical Center (MS 151), Research Building 7
830 Chalkstone Avenue, Providence, RI 02908
Aisling.Caffrey@va.gov | 401-273-7100 x2339

Education

August 2009 **Doctorate**, Pharmacoepidemiology and Pharmacoeconomics
College of Pharmacy, University of Rhode Island Kingston, RI

December 2005 **Master of Science**, Epidemiology, Concentration in Infectious Diseases
School of Public Health, State University of New York at Albany Rensselaer, NY

May 2003 **Bachelor of Arts**, Double Major in Psychology and Spanish Linguistics
Completion of Pre-Health Requirements, Magna Cum Laude
State University of New York at Albany Albany, NY

Academic Appointments

2018-present **Associate Professor of Health Outcomes (with Tenure)**
Department of Pharmacy Practice, College of Pharmacy
University of Rhode Island Kingston, RI

2015-present **Adjunct Assistant Professor of Health Services, Policy and Practice**
Department of Health Services, Policy and Practice
Brown University School of Public Health Providence, RI

2012-2018 **Assistant Professor of Health Outcomes**
Department of Pharmacy Practice, College of Pharmacy
University of Rhode Island Kingston, RI

2010-2012 **Adjunct Assistant Professor of Pharmacoepidemiology**
Department of Pharmacy Practice, College of Pharmacy
University of Rhode Island Kingston, RI

Research Appointments

2011-present **Director of Outcomes Research**
Rhode Island Infectious Diseases (RIID) Research Program
Providence Veterans Affairs Medical Center &
University of Rhode Island College of Pharmacy Providence, RI

2011-present **Investigator**, Research Health Science Specialist
Research Service, Providence Veterans Affairs Medical Center
United States Department of Veterans Affairs Providence, RI

Postgraduate Training

2009-2011	<p>Post-Doctoral Fellowship Concentration: Infectious Disease Pharmacoepidemiology and Health Outcomes Research Research Service, Providence Veterans Affairs Medical Center United States Department of Veterans Affairs</p>	Providence, RI
-----------	--	----------------

Professional Experience

- Research and Teaching Assistant, Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, 2007-2009
- Statistical Analyst & Telerand Protocol Specialist, Pfizer Consultant, Keane Inc., New London, CT, 2005-2007
- Bureau of HIV/AIDS Epidemiology Researcher, New York State Department of Health, Albany, NY, 2005
- Infection Control Project Researcher, Iroquois Healthcare Association, Clifton Park, NY, 2004

Original Research Publications in Peer Reviewed Journals

1. Thomason A, Pankey E, Nutt B, **Caffrey AR**, Zarate YA. Speech, language, and feeding phenotypes of SATB2-associated syndrome. *Clinical Genetics* 2019 (Epub ahead of print).
2. Appaneal HJ, **Caffrey AR**, Beganovic M, Avramovic S, LaPlante KL. Predictors of *Clostridioides difficile* recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings. *American Journal of Health System Pharmacists*. 2019; 76(9):581-590.
3. Appaneal HJ, **Caffrey AR**, Lopes VV, Crnich CJ, Dosa DM, LaPlante KL. National trends in the treatment of urinary tract infections among Veterans' Affairs Community Living Center residents. *Infection Control and Hospital Epidemiology* 2019 (Epub ahead of print).
4. Beganovic M, Cusumano JA, Lopes V, LaPlante KL, **Caffrey AR**. Comparative effectiveness of exclusive exposure to nafcillin or oxacillin, cefazolin, piperacillin/tazobactam, and fluoroquinolones among a national cohort of Veterans with methicillin-susceptible *Staphylococcus aureus* bloodstream infection. *Open Forum Infectious Diseases* 2019; 6(7):ofz270.
5. Zarate YA, Bosanko KA, **Caffrey AR**, et al. Mutation update for the SATB2 gene. *Human Mutation* 2019; 40(8):1013-1029.
6. **Caffrey AR**, Timbrook TT, Ali SR, Nizet V, Sakoulas G. Proton pump inhibitors do not influence clinical outcomes in patients with *Staphylococcus aureus* bacteremia. *Therapeutic Advances in Gastroenterology* 2019 12:1756284819834273.
7. **Caffrey AR**, Babcock ZR, Lopes VV, Timbrook TT, LaPlante KL. Heterogeneity in the treatment of bloodstream infections identified from antibiotic exposure mapping. *Pharmacoepidemiology and Drug Safety* 2019; 28(5):707-715.
8. Appaneal HJ, **Caffrey AR**, LaPlante KL. What is the role for metronidazole in the treatment of *Clostridium difficile* infection? Results from a national cohort study of Veterans with initial mild disease. *Clinical Infectious Diseases* 2018 Dec 18 (Epub ahead of print).
9. Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, **Caffrey AR**. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: an analysis of the US Food and Drug Administration adverse event reporting system. *Epilepsia* 2018; 59(12):2318-2324.
10. Pawar AM, LaPlante KL, Timbrook TT, **Caffrey AR**. Improved survival with continuation of statins in bacteremic patients. *SAGE Open Medicine* 2018;6:2050312118801707.

11. Appaneal HJ, **Caffrey AR**, Beganovic M, Avramovic S, LaPlante KL. Predictors of mortality among a national cohort of Veterans with recurrent *Clostridium difficile* infection. *Open Forum Infectious Diseases* 2018; 5(8):175.
12. Pawar AM, LaPlante KL, Timbrook TT, **Caffrey AR**. Optimal duration for continuation of statin therapy in bacteremic patients. *Therapeutic Advances in Infectious Diseases* 2018; 5(5):83-90.
13. Luther MK, Parente DM, **Caffrey AR**, Daffinee KE, Lopes VV, Martin ET, LaPlante KL. Clinical and genetic risk factors for biofilm-forming *Staphylococcus aureus* Antimicrobial Agents and Chemotherapy 2018; 62(5):e02252-17.
14. Appaneal HJ, **Caffrey AR**, Jiang L, Dosa D, Mermel LA, LaPlante KL. Antibiotic resistance rates for *Pseudomonas aeruginosa* clinical respiratory and bloodstream isolates among the Veterans Affairs healthcare system from 2009 to 2013. *Diagnostic Microbiology and Infectious Disease* 2018; 90(4):311-315.
15. Timbrook TT, **Caffrey AR**, Luther MK, Lopes V, LaPlante KL. Association of higher daptomycin dose (7mg/kg or greater) with improved survival in patients with methicillin-resistant *Staphylococcus aureus* bacteremia. *Pharmacotherapy* 2018; 38(2):189-196.
16. Ye Y, Larrat EP, **Caffrey AR**. Algorithms used to identify arrhythmias and sudden cardiac death associated with QT prolongation in retrospective studies: a systematic literature review. *Therapeutic Advances in Cardiovascular Disease* 2018; 12(2):39-51.
17. Luther MK, Timbrook TT, **Caffrey AR**, Dosa D, Lodise TP, LaPlante KL. Vancomycin plus piperacillin/tazobactam and acute kidney injury in adults: a systematic review and meta-analysis. *Critical Care Medicine* 2018; 46(1):12-20.
18. Timbrook TT, **Caffrey AR**, Ovalle A, Beganovic M, Curioso W, Gaitanis M, LaPlante KL. Assessments of opportunities to improve antibiotic prescribing in an emergency department: a period prevalence survey. *Infectious Diseases and Therapy* 2017; 6(4):497-505.
19. Lee EY, **Caffrey AR**. Thrombocytopenia with tedizolid and linezolid. *Antimicrobial Agents and Chemotherapy* 2017; 62(1):e01453-17.
20. **Caffrey AR**, DeAngelis J, Ward KE, Orr K, Morrill HJ, Gosciminski M, LaPlante KL, and the Rhode Island Pharmacy Pneumococcal Vaccination Education Group. A pharmacist-driven academic detailing program to increase adult pneumococcal vaccination. *Journal of the American Pharmacists Association* 2018; 58(3):303-310.
21. Parente DM, Timbrook TT, **Caffrey AR**, LaPlante KL. Inappropriate prescribing in outpatient healthcare: an evaluation of respiratory infection visits among Veterans. *Antimicrobial Resistance & Infection Control* 2017; 6:33.
22. Morton JB, Morrill HJ, LaPlante KL, **Caffrey AR**. Risk stacking of pneumococcal vaccination indications increases mortality in unvaccinated adults with *Streptococcus pneumoniae* infections. *Vaccine* 2017; 35(13):1692-1697.
23. Morrill HJ, Morton JB, **Caffrey AR**, Jiang L, Dosa D, Mermel LA, LaPlante KL. Antimicrobial resistance of *Escherichia coli* urinary isolates in the Veterans Affairs Healthcare System. *Antimicrobial Agents and Chemotherapy* 2017; 61(5):e02236-16.
24. Zarate YA, Kalsner L, Basinger A, Jones JR, Li C, Szybowski M, Xu ZL, Vergano S, **Caffrey AR**, et al. Genotype and phenotype in 12 additional patients with *SATB2*-Associated Syndrome. *Clinical Genetics* 2017; 92(4):423-429.
25. **Caffrey AR**, Timbrook TT, Noh E, Sakoulas G, Opal SM, Nizet V, LaPlante KL. Evidence to support continuation of statin therapy in patients with *Staphylococcus aureus* bacteremia. *Antimicrobial Agents and Chemotherapy* 2017; 61(3):e02228-16.
26. Morton JB, Morrill HJ, LaPlante KL, **Caffrey AR**. Predictors of mortality among unvaccinated Veterans nationally with serious *Streptococcus pneumoniae* infections. *American Journal of Preventive Medicine* 2017; 52(6):769-777.

27. McConeghy KW, **Caffrey AR**, Morrill HJ, Trivedi AN, LaPlante KL. Are non-allergic drug reactions commonly documented as medication "allergies"? A national cohort of Veterans' admissions from 2000 to 2014. *Pharmacoepidemiology and Drug Safety* 2017; 26(4):472-476.
28. Timbrook TT, Morton JB, McConeghy KW, **Caffrey AR**, Mylonakis E, LaPlante KL. The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review & meta-analysis. *Clinical Infectious Diseases* 2017; 64(1):15-23.
29. Morton JB, McConeghy R, Heinrich K, Gatto NM, **Caffrey AR**. Consensus of recommendations guiding comparative effectiveness research methods. *Pharmacoepidemiology and Drug Safety* 2016; 25(12):1354-60.
30. Morrill HJ, **Caffrey AR**, Gaitanis MM, LaPlante KL. Impact of a prospective audit and feedback antimicrobial stewardship program (ASP) at a Veterans Affairs medical center: a six-point assessment. *PLoS One*. 2016; 11(3):e0150795.
31. Morrill HJ, **Caffrey AR**, Jump RLP, Dosa D, LaPlante KL. Antimicrobial stewardship in long-term care facilities: a call to action. *Journal of the American Medical Directors Association* 2016; 17(2):183.
32. Morrill HJ, **Caffrey AR**, Noh E, LaPlante KL. Vancomycin dosing in obese and extremely obese patients. *Pharmacotherapy* 2015; 35(9):869-75.
33. **Caffrey AR**, Noh E, Morrill HJ, LaPlante KL. The effects of obesity on the comparative effectiveness of linezolid and vancomycin in suspected methicillin-resistant *Staphylococcus aureus* pneumonia. *Advances in Pharmacoepidemiology and Drug Safety* 2015; 4(1):1000176.
34. Morrill HJ, **Caffrey AR**, Noh E, LaPlante KL. Epidemiology of pneumococcal disease in a national cohort of older adults. *Infectious Diseases and Therapy* 2014; 3(1):19-33.
35. **Caffrey AR**, Morrill HJ, Puzniak LA, LaPlante KL. Predictors of clinical success among a national Veterans Affairs cohort with methicillin-resistant *Staphylococcus aureus* pneumonia. *Clinical Therapeutics* 2014; 36(4):552-9.
36. **Caffrey AR**, Morrill HJ, Puzniak LA, LaPlante KL. Comparative effectiveness of linezolid and vancomycin among a national Veterans Affairs cohort with methicillin-resistant *Staphylococcus aureus* pneumonia. *Pharmacotherapy* 2014; 34(5):473-80.
37. Alshammari TM, Larrat EP, Morrill HJ, **Caffrey AR**, Quilliam BJ, LaPlante KL. Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study. *American Journal of Health-System Pharmacy* 2014; 71:37-43.
38. **Caffrey AR**. The role of comparative effectiveness research in medicine and health. *Medicine and Health, Rhode Island* 2012; 95(9):273-4.
39. Li E, Greenberg PB, Tseng V, **Caffrey AR**, Woodmansee SB, Wu WC, Friedmann PD, LaPlante KL. In vitro coagulation effects of ophthalmic doses of bevacizumab. *Journal of Ocular Pharmacology and Therapeutics* 2012; 28(3):219-21.
40. **Caffrey AR**, LaPlante KL. Changing epidemiology of methicillin-resistant *Staphylococcus aureus* in the Veterans Affairs Health System, 2002-2009. *Infection* 2012; 40(3):291-7.
41. **Caffrey AR**, Woodmansee SB, Crandall N, Tibert C, Fielding C, Mikolich DJ, Vezeridis MP, LaPlante KL. Low adherence to outpatient pre-operative methicillin-resistant *Staphylococcus aureus* decolonization therapy. *Infection Control and Hospital Epidemiology* 2011; 32(9):930-2.
42. **Caffrey AR**, Quilliam BJ, LaPlante KL. Risk factors associated with mupirocin resistance in methicillin-resistant *Staphylococcus aureus*. *Journal of Hospital Infection* 2010; 76(3):206-10.
43. **Caffrey AR**, Quilliam BJ, LaPlante KL. Comparative effectiveness of linezolid and vancomycin among a national cohort of patients infected with methicillin-resistant *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy* 2010; 54(10):4394-400.

*Ranked among most significant publications on infectious diseases pharmacotherapy in 2010. Hirsch EB, Cottreau JM, Ikwuagwu JO, et al. Significant publications on infectious diseases pharmacotherapy in 2010. American Journal of Health System Pharmacy 2011; 68:2075-85.

44. LaPlante KL, **Caffrey AR**, Gupta K. Prevention of surgical-site infections. New England Journal of Medicine 2010; 362(16):1540-1; author reply 2-3.
45. Kogut S, **Caffrey A**, Pezzullo L. Use of angiotensin-converting enzyme inhibitors / angiotensin receptor blockers and lipid-lowering therapies among Rhode Islanders with diabetes enrolled in Medicare Part D plans in 2006 and 2007. Medicine and Health, Rhode Island 2009; 92(11):373-6.

Oral Presentations at National & International Meetings

1. Babcock ZR, Kogut SJ, **Caffrey AR**. Cost predictors among hospitalized pediatric patients with pneumonia. Presented at the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), August 25, 2017; Montreal, Canada.
2. Ye Y, Larrat EP, LaPlante KL, **Caffrey AR**. Azithromycin and ventricular arrhythmia: a national claims-based cohort study. Presented at the 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), August 25, 2017; Montreal, Canada.
3. **Caffrey AR**, Timbrook TT, Sakoulas G, LaPlante KL. Do proton pump inhibitors impact clinical outcomes in Staphylococcus aureus bacteremia? Presented at the 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), August 28, 2016; Dublin, Ireland. Abstract available in Pharmacoepidemiology and Drug Safety 2016; 25(S3):S469-70.
4. Morrill HJ, Morton JB, Wang Y, LaPlante KL, **Caffrey AR**. Differences in characteristics and outcomes among Veterans with *Clostridium difficile* infection (CDI) by treatment. Presented at the 2016 Microbe Meeting of the American Society of Microbiology, June 16-20, 2016; Boston, MA.
5. **Caffrey AR**, Noh E, LaPlante KL. Exposure mapping of antimicrobials for the treatment of methicillin-resistant *Staphylococcus Aureus* (MRSA) bacteremia. Presented at the 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), August 25, 2015; Boston, MA. Abstract available in Pharmacoepidemiology and Drug Safety 2015; 24:205.
6. Gomes DM, **Caffrey AR**, LaPlante KL. Education and presence of an infectious diseases (ID) pharmacist in an outpatient primary care clinic. Presented at the 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), August 24, 2015; Boston, MA. Abstract available in Pharmacoepidemiology and Drug Safety 2015; 24:17.
7. Morrill HJ, **Caffrey AR**, Jiang L, Dosa D, LaPlante KL. Trends in *Enterobacteriaceae* resistance in the Veterans Affairs (VA) New England Healthcare System. Presented at the 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), August 24, 2015; Boston, MA. Abstract available in Pharmacoepidemiology and Drug Safety 2015; 24:17-8.
8. Noh E, Dreyer NA, Ahn J, Alshammari TM, Ritchey ME, Layton B, **Caffrey AR**. Guidelines and recommendations for comparative effectiveness research (CER) methods: international assessment and exchange. Symposium presented at the 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), October 24-27, 2014; Taipei, Taiwan. Abstract available in Pharmacoepidemiology and Drug Safety 2014; 23(S1):S205.
9. **Caffrey AR**, Noh E, Morrill HJ, LaPlante KL. The effects of obesity on the comparative effectiveness of linezolid and vancomycin in MRSA pneumonia. Presented at the 30th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), October 24-27, 2014; Taipei, Taiwan. Abstract available in Pharmacoepidemiology and Drug Safety 2014; 23(S1):S16-7.

5. Funding Agency: The Medicines Company
Title: Acute bacterial skin and skin structure infections (ABSSSI) among Veterans treated with vancomycin: treatment epidemiology after hospital discharge
Role: Principal Investigator Project Period: 09/2016-09/2017
6. Funding Agency: Department of Veterans Affairs, Health Services Research & Development
Title: Improving antimicrobial stewardship in Veteran Affairs (VA) community living centers
Role: Co-Investigator (PI Dosa) Project Period: 10/2016-03/2021
7. Funding Agency: Pfizer Independent Grants for Learning & Change
Title: Beyond information: science-based communication targeted to decrease disparities in adult pneumococcal vaccination rates
Role: Co-Investigator (PI LaPlante) Project Period: 09/2015-08/2017
8. Funding Agency: Investigator Initiated Research Grant, Merck
Title: Burden of *Clostridium difficile* infection throughout the Veterans Affairs Healthcare System
Role: Co-Investigator (PI LaPlante) Project Period: 05/2015-12/2016
9. Funding Agency: Pfizer Independent Grants for Learning & Change
Title: Addressing educational & coordination barriers for adult pneumococcal disease prevention in Rhode Island
Role: Co-Investigator (PI LaPlante) Project Period: 01/2013-12/2015
10. Funding Agency: American Association of Colleges of Pharmacy (AACP) New Investigator Award
Title: Comparative effectiveness of antimicrobials in *Staphylococcus aureus* bacteremia
Role: Principal Investigator Project Period: 01/2013-5/2015
11. Funding Agency: Advancing Science Through Pfizer-Investigator Research Exchange (ASPIRE) Antibacterial Research Competitive Research Grant Award
Title: The effects of obesity on the comparative effectiveness of linezolid and vancomycin in methicillin-resistant *Staphylococcus aureus* pneumonia
Role: Co-Investigator (PI LaPlante) Project Period: 01/2013-12/2013
12. Funding Agency: Advancing Science Through Pfizer-Investigator Research Exchange (ASPIRE) Vaccines Competitive Research Grant Award
Title: Burden of pneumococcal disease in a national cohort of adults 50 years and older: focus on incidence and prevalence of disease co morbidities
Role: Co-Investigator (PI LaPlante) Project Period: 01/2013-12/2013
13. Funding Agency: Veteran Affairs New England Healthcare System Early Career Development Award, United States Department of Veterans Affairs
Title: Comparative effectiveness of antimicrobials for the treatment of MRSA
Role: Principal Investigator Project Period: 02/2011-02/2013

Invited Lectures

- “Statistics in Clinical Outcomes Research”, Geriatrics Division Lecture Series, Rhode Island Hospital, Providence, RI. Audience: Geriatrics Fellows and Faculty of Brown University, 2014-present.
- “Treatment Epidemiology”, Seminar Series, University at Albany School of Public Health, Albany, NY. Audience: Students and Faculty of the Epidemiology Department, 2014.
- “What every clinician should know about evaluating clinical research”, Noon Conference, Memorial Hospital, Pawtucket, RI. Audience: Internal Medicine Residents, Pharmacy and Medical Students, 2012-2015.

- “Highlighting Recent Pharmacoepidemiologic Research of MRSA”, Infectious Diseases Conference, Miriam Hospital, Providence, RI. Audience: Infectious Disease Physicians, Infectious Disease Fellows and Faculty of Brown University, 2011-2012.

University and Hospital Teaching Roles

- Major Professor for M.S. and Ph.D. students specializing in Health Outcomes (formerly Pharmacoepidemiology and Pharmacoconomics), Graduate Program in Pharmaceutical Sciences, College of Pharmacy
- University of Rhode Island, College of Pharmacy, Department of Pharmacy Practice, Courses
 - PHP 405 Epidemiology in Health Care (4 credits)
 - PHP 550 Pharmacoepidemiology (3 credits)
 - PHC 693/694 Graduate Seminar (1 credit)
- University of Rhode Island, College of Pharmacy, Department of Pharmacy Practice, Lectures
 - PHP 305 Drug Information and the Analysis of Literature: Epidemiologic study designs and methods, linear regression, logistic regression, event-related analysis
 - PHP 317 Pharmacy Practice in Contemporary Health Care: Public health, epidemiologic study designs, and epidemiologic methods
 - PHP 497/498 Special Problems: Research in epidemiology and pharmacoepidemiology
 - PHC 502 Drug Development: Clinical Trials, Drug Safety, and Pharmacoepidemiology
 - PHP 503 Health Systems I: Public health, describing populations, epidemiologic study designs, epidemiologic methods
 - PHP 516 Pharmacy Practice Laboratory II: Pharmacoepidemiology and pharmacovigilance
 - PHP 540 Principles, Methods, and Applications of Epidemiology: Epidemiologic study designs and methods
 - PHC 599 Master's Thesis Research
 - PHP 697/698 Research in Pharmacy: Research in Epidemiology and Pharmacoepidemiology
 - PHC 699 Doctoral Dissertation Research
- Providence Veterans Affairs Medical Center
 - Mentoring and teaching first and second year pharmacy residents, sixth year pharmacy students: interpreting clinical research, research study designs, methodology, and statistics
- Associate Director of the Post-Doctoral Clinical Research Outcomes Fellowship Program in Antimicrobial Stewardship, Providence Veterans Affairs Medical Center, United States Department of Veterans Affairs
- Director, Post-Doctoral Fellowship in Health Services Research, Providence Veterans Affairs Medical Center, United States Department of Veterans Affairs
- Mentor, Advanced Health Research Fellowship, Providence Veterans Affairs Medical Center, United States Department of Veterans Affairs

Mentored Research Fellows

- Emily Bodo, Pharm.D., Post-Doctoral Fellow, Outcomes in Antimicrobial Stewardship (June 2018-June 2020), funded by the Veterans Health Administration National Office of Academic Affiliations (OAA)
- Jaclyn Cusumano, Pharm.D., Post-Doctoral Fellow, Outcomes in Antimicrobial Stewardship (July 2017-June 2019), funded by the Veterans Health Administration National Office of Academic Affiliations (OAA)

- Keith Corl, M.D., Advanced Health Research Fellow (August 2017-December 2018), funded by the Veterans Health Administration National Office of Academic Affiliations (OAA)
- Maya Beganovic, Pharm.D., MPH, Post-Doctoral Fellow, Outcomes in Antimicrobial Stewardship (July 2016-June 2018), funded by the Veterans Health Administration National Office of Academic Affiliations (OAA)
- Megan Luther, Pharm.D., Advanced Health Research Fellow (August 2015-August 2017), funded by the Veterans Health Administration National Office of Academic Affiliations (OAA)
- Kevin McConeghy, Pharm.D., MS, BCPS, Advanced Health Research Fellow (August 2015-August 2017), funded by the Veterans Health Administration National Office of Academic Affiliations (OAA)
- Tristan Timbrook, Pharm.D., MBA, BCPS, Post-Doctoral Fellow, Outcomes in Antimicrobial Stewardship (August 2015-July 2017), funded by the Veterans Health Administration National Office of Academic Affiliations (OAA)
- Jacob Morton, Pharm.D., MBA, BCPS, Post-Doctoral Fellow, Outcomes in Antimicrobial Stewardship (July 2014-June 2016), funded by the Veterans Health Administration National Office of Academic Affiliations (OAA)
- Eunsun Noh, Ph.D., Post-Doctoral Fellow, Health Services Research (September 2013-May 2015), funded by multiple research grants
- Diane Gomes, Pharm.D., Post-Doctoral Fellow, Outcomes in Antimicrobial Stewardship (July 2013-June 2015), funded by the Veterans Health Administration National Office of Academic Affiliations (OAA)
- Haley Morrill, Pharm.D., Post-Doctoral Fellow, Outcomes in Antimicrobial Stewardship (July 2012-June 2014), funded by the Veterans Health Administration National Office of Academic Affiliations (OAA)

University Service

- Voting Member, Institutional Review Board Member, University of Rhode Island, 2018-present
- Chair, Data Security and Database Management Committee, Health Outcomes Subcommittee (formerly Pharmacoepidemiology and Pharmacoeconomics Subcommittee), College of Pharmacy, University of Rhode Island, 2012-present
- Member, Research and Graduate Studies Committee, College of Pharmacy, University of Rhode Island, 2012-2015
- Member, Health Outcomes Subcommittee (formerly Pharmacoepidemiology and Pharmacoeconomics Subcommittee), College of Pharmacy, University of Rhode Island, 2012-present

Hospital Service

- Chair, Institutional Review Board, Providence Veterans Affairs Medical Center, 2016-present
- Voting Member, Institutional Review Board, Providence Veterans Affairs Medical Center, 2013-2016

Professional Affiliations

- Member, Academic Council, International Society for Pharmacoepidemiology, 2013-present
- Member, International Society for Pharmacoeconomics and Outcomes Research, 2013-2014
- Member, American Association of Colleges of Pharmacy, 2012-2014
- Member, Comparative Effectiveness Research Special Interest Group, International Society for Pharmacoepidemiology, 2010-present
- Member, American Society for Microbiology, 2009-2013, 2016-present

- Member, International Society for Pharmacoepidemiology, 2008-present

Professional Organization Appointments

- Past Chair, Comparative Effectiveness Research Special Interest Group, International Society for Pharmacoepidemiology, 2014
- Chair, Comparative Effectiveness Research Special Interest Group, International Society for Pharmacoepidemiology, 2013
- Chair and Judge, Comparative Effectiveness Research Special Interest Group Poster Walk, 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), International Society for Pharmacoepidemiology, 2013
- Faculty Advisor for University of Rhode Island Student Chapter, International Society for Pharmacoepidemiology, 2013-present
- URI Academic Member Representative, International Society for Pharmacoepidemiology, 2013, 2015-2016
- Chair-Elect, Comparative Effectiveness Research Special Interest Group, International Society for Pharmacoepidemiology, 2012
- Co-Chair and Judge, Comparative Effectiveness Research Special Interest Group Poster Walk, 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), International Society for Pharmacoepidemiology, 2012

Peer Review

- Peer-Reviewer, Lancet Infectious Diseases, 2019-present
- Peer-Reviewer, New England Journal of Medicine, 2017-2018
- Peer-Reviewer, JAMA Internal Medicine, 2016
- Peer-Reviewer, Antimicrobial Agents and Chemotherapy, 2010
- Peer-Reviewer, Pharmacoepidemiology and Drug Safety, 2009-present
Outstanding Reviewer Award, 2009, 2012, 2013
- Peer-Reviewer, Pharmacotherapy, 2008, 2015

Honors and Awards

- New Investigator Award, American Association of Colleges of Pharmacy, 2013
- Performance Award, Providence Veterans Affairs Medical Center, 2012-2014
- International Society for Pharmacoepidemiology Travel Scholarship for the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), August 13-17, 2011 in Chicago, IL
- American Society of Microbiology, Infectious Diseases Fellow Grant, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 11-15th, 2010 in Boston, MA
- International Society for Pharmacoepidemiology Travel Scholarship for the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), August 19-22, 2010 in Brighton, England
- Takeda Pre-Doctoral Research Fellowship Grant, 2008-2009
- Wal-Mart Conference Scholarship Recipient, American Association of Colleges of Pharmacy, 2008

Skills Profile

- Languages: Highly proficient in reading, writing, and speaking Spanish
- Application Packages: Unity Clinical, SPSS, Epi-Info, MapInfo, ArcView, TreeAge
- Databases: CDARS, National Veterans Affairs Databases through the Austin Mainframe and VINCI (Medical SAS, DSS, CDW, Vital status, Crosswalk), VistA Fileman
- Programming Languages: SAS, SQL, Unix, R, JCL; Operating Systems: Windows, Unix, Adobe, MS Office